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Despite the tremendous advances in the treatment of childhood solid tumors, rhabdomyosarcoma (RMS)
continues to provide a therapeutic challenge. Children with metastatic or relapsed disease have a disease-free
survival rate under 30%. Focal adhesion kinase (FAK) is a nonreceptor tyrosine kinase that is important in many
facets of tumorigenesis. Signaling pathways both upstream and downstream to FAK have been found to be
important in sarcoma tumorigenesis, leading us to hypothesize that FAK would be present in RMS and would
impact cellular survival. In the current study, we showed that FAK was present and phosphorylated in pediatric
alveolar and embryonal RMS tumor specimens and cell lines. We also examined the effects of FAK inhibition upon
two RMS cell lines utilizing parallel approaches including RNAi and small molecule inhibitors. FAK inhibition
resulted in decreased cellular survival, invasion, and migration and increased apoptosis. Furthermore, small
molecule inhibition of FAK led to decreased tumor growth in a nude mouse RMS xenograft model. The findings
from this study will help to further our understanding of the regulation of tumorigenesis in RMS and may provide
desperately needed novel therapeutic strategies for these difficult-to-treat tumors.
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Rhabdomyosarcoma (RMS) is a mesodermal cancer that undergoes
partial skeletal muscle differentiation. RMS is the fourth most
common solid tumor in children, with two thirds of the patients
being less than 10 years of age at diagnosis [1]. These tumors are not
restricted to children, and it is estimated that over 40% of all RMSs
are actually diagnosed in adults [2]. RMS was long considered to have
two main subtypes: alveolar and embryonal. Traditionally, the
alveolar subtype was considered the more aggressive tumor with
poorer outcomes. Current data have shown that it is actually the
presence of a PAX-FOXO1 gene fusion that portends the worse
prognosis [3]. Overall survival for RMS has not improved
significantly since the 1990s, and survival is currently less than
30% for children with metastatic disease [4]. Survival for adults is
equally dismal; over 70% of those diagnosed with RMS will expire
from their disease [2]. Novel, less toxic, and innovative therapies are
clearly needed.
Focal adhesion kinase (FAK) is a nonreceptor tyrosine kinase that
localizes to focal adhesions and controls a number of cellular pathwaysinvolved in cell adhesion, migration, invasion, proliferation, and
survival [5–8]. FAK activation occurs when cell surface integrins bind
to β subunits of FAK, resulting in phosphorylation and binding of Src
family kinases [5]. FAK also has an autophosphorylation site at the
tyrosine 397 (Y397) residue [9] that leads to increased cell survival via
inhibition of detachment-activated apoptosis, or anoikis [10]. FAK
inhibition with small interfering RNA (siRNA) [11,12] has been
264 FAK supports rhabdomyosarcoma tumorigenicity Waters et al. Translational Oncology Vol. 9, No. 4, 2016shown to decrease tumor cell survival. Additionally, abrogation of
FAK phosphorylation at Y397 using dominant negative constructs
[13] and small molecule inhibitors [12,14–16] has been shown to
decrease tumor cellular migration, invasion, and survival.
A previous study with a fibrosarcoma cell line showed that FAK
activation occurred in response to a pressure stimulus [17]. This
finding led us to hypothesize that RMS would express FAK and that
inhibition of FAK would result in a less aggressive phenotype. We
demonstrated that abrogation of FAK in both alveolar (PAX-FOXO1
gene fusion positive) [18] and embryonal (PAX-FOXO1 gene fusion
negative) RMS tumor cell lines resulted in decreased tumor cell
survival in vitro and decreased xenograft growth in vivo. From these
studies, we concluded that targeting FAK may prove to be a useful
therapeutic adjunct in the treatment of these aggressive solid tumors.
Materials and Methods
Cells and Cell Culture
All cell lines were maintained in standard culture conditions at 37°C
and 5% CO2. RD human embryonal RMS cells (CCL-136; American
Type Culture Collection, ATCC, Manassas, VA) were maintained in
Dulbecco’s modified Eagle’s medium containing 10% fetal bovine serum
(S11150; Atlanta Biologicals, Flowery Branch, GA), 4 mM L-glutamine,
1 μM nonessential amino acids, and 1 μg/ml penicillin/streptomycin.
SJCRH30 human alveolar RMS cells (PAX-FOXO1 fusion positive) [18]
(CRL-2061, ATCC) were maintained in RPMI 1640 medium
supplemented with 10% fetal bovine serum (Atlanta Bioligcals) and 1
μg/ml penicillin/streptomycin. All cell lines were obtained from ATCC
within the last 2 years and were mycoplasma free.
Antibodies and Reagents
Monoclonal mouse anti-FAK (4.47, 05-0537) antibody was from
Millipore (EMD Millipore, Billerica, MA), and rabbit polyclonal
anti-phospho-FAK (Y397, 71-7900) antibody was from Invitrogen
(Invitrogen Corp., Carlsbad, CA). Rabbit polyclonal anti-cleaved PARP
(9542) and rabbit monoclonal anti-PARP (9532) antibodies were
obtained from Cell Signaling Technology (Danvers, MA). Monoclonal
mouse anti-β-actin was from Sigma (A1978; Sigma-Aldrich Corp., St.
Louis, MO). The small molecule PF-573,228 (C22H20F3N5O3S) was
purchased from Santa Cruz Biotechnology (Santa Cruz, CA), and the
small molecule 1,2,4,5-benzenetetraamine tetrahydrochloride (Y15)
(C6H10N4∙4ClH) from Sigma.
Human Tissue Specimens
Formalin-fixed, paraffin-embedded pediatric RMS tumor speci-
mens were obtained from the tumor repository at our institution
under waiver of informed consent from the University of Alabama,
Birmingham, institutional review board approval (X1009300009).
Immunohistochemistry Human Specimens
Formalin-fixed, paraffin-embedded human tumor specimens were
sectioned into 6-μM sections and baked at 70°C for 1 hour on
positive slides. Slides were deparaffinized, steamed, sections quenched
with 3% hydrogen peroxide and blocked with blocking buffer (BSA,
powdered milk, Triton X-100, PBS) for 30 minutes at 4°C. The
primary antibodies anti-FAK (4.47), 1:500 (05-537, Millipore), and
anti-phospho-FAK (Y397), 1:500 (04-974, Millipore), were added
and incubated overnight at 4°C. After washing with PBS, the
secondary antibodies for mouse (ImmPress MP-7402; Vector
Laboratories, Burlingame, CA) and rabbit (Super Picture HRP,87-9263; Zymed Laboratories, Invitrogen) were added (1:10
dilution) for 1 hour at 22°C. The staining reaction was developed
with VECTASTAIN Elite ABC kit (PK-6100, Vector Laboratories),
TSA (biotin tyramide reagent, 1:400; PerkinElmer, Inc., Waltham,
MA), and DAB (Metal Enhanced DAB Substrate, Thermo Fisher
Scientific). Slides were counterstained with hematoxylin. Negative
controls [mouse IgG (1 μg/ml, Invitrogen) or rabbit IgG (1 μg/ml,
EMD Millipore)] were included with each run.
Immunohistochemical Scoring
Stained slides of human tumors were reviewed and scored by two
pathologists (S.M., E.M.M.) blinded to the patients. Specimens were
scored based upon the intensity of staining and the percentage of tumor
cells staining positive and assigned a score from 0 to 3. Scores ranged from
negative (no staining) to weak (1), moderate (2), and strong (3).
Immunoblotting
Western blots were performed as previously described [16,19].
Briefly, whole cell lysates or homogenized xenograft specimens were
isolated using RIPA [10 mM Tris base pH 7.2, 150 mM NaCl, 1%
Na-deoxycholate, 1% Triton X-100, 0.1% sodium dodecyl sulfate
(SDS)] lysis buffer supplemented with protease inhibitors (Sigma),
phosphatase inhibitors (Sigma), and phenylmethanesulfonylfluoride.
Lysates were cleared by centrifugation at 14,000 rpm for 30 minutes
at 4°C. Protein concentrations were determined using Bio-Rad kit
(Bio-Rad, Hercules, CA) and separated by electrophoresis on sodium
dodecyl sulfate polyacrylamide (SDS-PAGE) gels. Antibodies were
used according to manufacturer's recommended conditions. Molec-
ular weight markers (Bio-Rad) confirmed the expected size of the
target proteins. Immunoblots were developed with Luminata Classico
or Crescendo ECL (EMD Millipore). Blots were stripped with
stripping solution (Bio-Rad) at 37°C for 15 minutes and then
reprobed with selected antibodies. Equal protein loading was
confirmed with immunoblotting with antibody to β-actin.
siRNA Transfection
siRNAs were obtained from Dharmacon (Dharmacon, GE
Healthcare, Layfayette, CO) for the following FAK target sequences:
FAK2, 5′-GGGCAUCAUUCAGAAGAUA-3′; FAK3, 5′-UAGUA-
CAGCUCUUGCAUAU-3′; FAK4 5′-GGACAUUAUUGGCCA-
CUGU-3′. Cells (3 × 105 cells per well) were treated with HiPerFect
(Qiagen, Valencia, CA) alone; HiPerFect plus 20 nM negative
control siRNA (1027310, Qiagen); or HiPerFect plus FAK siRNA2,
3, or 4 (20 nM) according to manufacturer's protocol, incubated for
24 to 48 hours following transfection, and then used for experiments.
FAK inhibition by siRNA was confirmed using immunoblotting.
Cell Viability Assays
Cell viability was measured with alamarBlue assay. Briefly, 1.5 × 103
cells per well were plated on 96-well culture plates; allowed to attach; and
treated with RNAi inhibition, PF-573,228 (PF, Santa Cruz), or
1,2,4,5-benzenetetraamine tetrahydrochloride (Y15, Sigma). Following
treatment, 10μl of alamarBlue dye (Invitrogen)was added and after 4 to 6
hours; the absorbance at 595 nmwasmeasured using a kinetic microplate
reader (BioTek Gen5; BioTek Instruments, Winooski, VT). Viability
was reported as fold change.
Proliferation
Proliferation was measured with CellTiter 96 assay according to
manufacturer’s recommendations (CellTiter 96 AQueous One
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RD or SJCRH30 cells (5 × 103 cells per well) were treated with
HiPerFect (Qiagen) alone; control negative siRNA (siNeg, Qiagen);
or siFAK2, 3, or 4 (Dharmacon) for 48 hours. Cells were stained with
10 μl of CellTiter 96 dye, and the absorbance at 490 nm was
measured using a kinetic microplate reader (BioTek Gen5). For
experiments with PF (Santa Cruz) and Y15 (Sigma), similar cell
numbers were plated, and cells were treated for 48 hours with
increasing concentrations of PF or Y15. Proliferation was evaluated
with CellTiter 96 and reported as fold change.
Migration Assay
Twelve-well culture plates (TransWell; Corning Inc., Lowell, MA)
with 8-μm micropore inserts were used. The bottom side of the insert
was coated with collagen type I (10 mg/ml, 50 μl for 4 hours at 37°C).
RD or SJCRH30 cells were treated with PF-573,228 or Y15 and placed
into the upper well at a concentration of 5 × 103 cells per well and
allowed to migrate for 24 hours. The inserts were then fixed with 3%
paraformaldehyde and stained with crystal violet, andmigrated cells were
counted with a light microscope. Migration was reported as fold change.
Invasion Assay
Similar tomigration, 12-well culture plates (TransWell, Corning) with
8-μmmicropore inserts were used. The top side of the insert was coated
withMatrigel (BDBiosciences, San Jose, CA) (1mg/ml, 50μl for 4 hours
at 37°C). RD or SJCRH30 cells (5 × 103 cells per well) were treated with
PF-573,228 or Y15 and plated into the upper well. Cells were allowed to
invade for 48 hours. The inserts were then fixed with 3%
paraformaldehyde and stained with crystal violet, and cells were counted
with a light microscope. Invasion was reported as fold change.
In Vivo Tumor Growth
All experiments were performed in strict accordance with the
recommendations in the Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health. The protocol was
approved by the University of Alabama, Birmingham, Institutional
Animal Care and Use Committee (120209355) in compliance with
institutional, national, and National Institutes of Health animal use
guidelines. Six-week-old female athymic nude mice (Harlan
Laboratories, Inc., Chicago, IL) were maintained in the SPF animal
facility with standard 12-hour light/dark cycles and allowed chow and
water ad libitum. Human RMS cells, RD (2.5 × 106 cells/100 μl of
sterile PBS), were injected into the subcutaneous space of the right
flank (n = 25). Tumors were measured every 2 days, and tumor
volumes were calculated with the standard formula of [(width)2 ×
length]/2, where width was the shorter length. When tumors reached
200 mm3, the animals were randomized to receive daily intraperi-
toneal injections of either control vehicle (saline, 100 μl, n = 10) or
1,2,4,5-benzenetetraamine tetrahydrochloride (Y15, 30 mg/kg per
day, 100 μl, n = 15). This dose was chosen based upon prior in vivo
studies with Y15 [14–16,19]. Y15 treatment continued for 2 weeks, at
which time control animalsmet IACUCparameters for euthanasia and all
animals were euthanized with CO2 and bilateral thoracotomy and the
flank tumors harvested. The incidence of tumor occurrence was not
different between the treatment groups, and all animals (n = 25)
developed tumors. Data were reported as change in tumor volume from
initiation of treatment. This same experiment was also completed with
the SJCRH30 cell line but with fewer cells injected (2.0 × 106 cells/100μl
of sterile PBS) because of their growth characteristics.Immunohistochemistry Murine Samples
Formalin-fixed, paraffin-embedded tumor blocks of murine RMS
xenografts were cut in 6-μM sections. The slides were baked for 1
hour at 70°C, deparaffinized, rehydrated, and steamed. The sections
were then quenched with 3% hydrogen peroxide and blocked with
PBS-blocking buffer. Ki67 staining for cellular proliferation in the
tumor xenografts was completed. The primary anti-Ki67 rabbit
polyclonal antibody (ab15580; Abcam, Cambridge, MA) was added
(1:200 dilution) and incubated overnight at 4°C. After washing with
PBS, the secondary antibody (donkey anti-rabbit, 1:400; Jackson
ImmunoResearch Laboratories, West Grove, PA) was added for 1
hour at 22°C. The staining reactions were developed with
VECTASTAIN Elite ABC kit (PK-6100, Vector Laboratories),
TSA (1:400, PerkinElmer, Inc.), and DAB (ImmPACT DAB, Vector
Laboratories). Slides were counterstained with hematoxylin. A
negative control [rabbit IgG (1 μg/ml, EMD Millipore)] was
included with each run.
Data Analysis
Data reported as mean ± standard error of the mean. Densitometry
of Western blots was performed using the image histogram analysis
feature of Adobe Photoshop software (Adobe Systems Inc., San Jose,
CA). Ki67 staining was quantified by ImageJ software (http://rsb.
info.nih.gov/ij/). Positive Ki67 staining was reported as percent
positive staining cells per high-power field after counting 10 random
fields of view per specimen. Student’s t test, Fisher’s exact test, or
analysis of variance was used as appropriate to compare data between
groups. Statistical significance was determined at the P b .05.
Results
FAK in Pediatric RMS Specimens and Cell Lines
To determine if FAK may be clinically relevant, immunohisto-
chemistry was performed on 15 human pediatric RMS tumor
specimens, including 6 alveolar and 9 embryonal histologic types.
FAK staining was detected in all six of the alveolar and in eight of the
nine embryonal specimens. In addition, FAK was phosphorylated in
all 14 of the specimens in which it was detected. Representative
photomicrographs are presented in Figure 1A (20×) (Figure 1A,
brown stain). There were no significant differences noted in the stain
scores of either pY397FAK (Figure 1B, bar = median) or FAK
between the two subtypes (Figure 1C, bar = median). Immunoblot-
ting was used to evaluate FAK expression in the SJCRH30 and RD
RMS tumor cell lines. FAK was detected in both of the cell lines and
was phosphorylated (Figure 1D).
Decreased RMS Cell Viability and Proliferation with
FAK siRNA
We initially studied the effects of FAK silencing with siRNA on
RD and SJCRH30 cell viability. RD and SJCRH30 cells were treated
with HiPerFect plus negative control siRNA (siNeg, 20 nM) or
HiPerFect plus siRNA specific for FAK (siFAK2, 3, or 4; 20 nM) for
48 hours. siRNA treatment of the cell lines successfully inhibited
FAK protein expression (Figure 2A). Cellular viability was measured
using alamarBlue following FAK knockdown with siRNA. In the RD
cell line treated with siFAK, cell viability decreased significantly
following treatment (1.0 ± 0 vs 0.87 ± 0.0005 and 0.64 ± 0.01, P ≤
.01, siNeg vs siFAK3 or siFAK4, respectively) (Figure 2B). In the
SJCRH30 cell line, cell viability was also decreased significantly (1.0 ±
0.03 vs 0.72 ± 0.005 and 0.71 ± 0.002, P ≤ .01, siNeg vs siFAK2 or
Figure 1. FAK in pediatric RMS specimens and cell lines. (A) Immunohistochemistry staining with antibodies specific for FAK and
pY397FAK was performed on 15 formalin-fixed, paraffin-embedded human pediatric RMS tumor specimens (6 alveolar and 9 embryonal).
Representative photomicrographs presented at 20× show staining for FAK (lower panels) and pY397 FAK (upper panels) in both
histologic types. Negative controls (mouse or rabbit IgG) were included with each run (inserts, bottom left upper and lower panels). (B)
Immunohistochemical staining was scored. Stain scores for pY397FAK staining were similar between ARMS and ERMS specimens. Bars
represent the mean stain scores. (C) Immunohistochemical staining was scored for FAK staining. Stain scores for FAK were not different
between ARMS and ERMS specimens. The bar represents the median stain scores. (D) Immunoblotting for pY397FAK and total FAK was
performed on SJCRH30 and RD RMS tumor cell lysates. FAK was detected in both cell lines and was phosphorylated.
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proliferation was affected by FAK inhibition, CellTiter 96 was
performed following 48-hour treatment with siRNA (20 nM). Both
the RD and the SJCRH30 cell lines showed a significant decrease in
proliferation following FAK knockdown with siRNA when compared
with siNeg (Figure 2C).
PF-573,228 Decreased Cell Survival and Motility
To examine the effects of FAK inhibition, we utilized a small
molecule FAK inhibitor, PF-573,228 (PF). PF targets the
ATP-binding pocket of FAK and has been shown in multiple cell
lines to block FAK phosphorylation at the tyrosine 397 (Y397) site
[20]. Cells were treated with PF at increasing concentrations.
Immunoblotting was utilized to confirm pY397FAK inhibition.
After 48 hours of treatment, PF decreased FAK phosphorylation
(Y397) in both cell lines (Figure 3A). AlamarBlue assays were used to
assess the effects of PF on cell survival. Both RD and SJCRH30 cell
lines showed significantly decreased cell survival following treatment
with PF for 48 hours (Figure 3B). The calculated LD50 for PF was 28
μM in the RD cell line and 40 μM in the SJCRH30 cell line. To
determine whether the PF-induced cell death was due to apoptosis,immunoblotting for cleaved PARP was examined. There was an
increase in cleaved PARP expression in both cell lines after treatment
with PF (Figure 3C), indicating that decreased cell viability was due to
apoptosis. Furthermore, cleavage of caspase 3 was measured with a
detection kit and confirmed apoptosis in both cell lines following PF
treatment (Figure 3D). We also examined cell proliferation with
CellTiter 96 assays. There was a significant decrease in proliferation in
both cell lines following treatment with PF for 48 hours (Supplemental
Data Figure S1A).
FAK also affects cell migration and invasion [12,21]; therefore, we
wished to determine if these entities would be affected by FAK
inhibition in RMS cell lines. For invasion, RD and SJCRH30 cell
lines were treated with increasing concentrations of PF and allowed
to invade through a Matrigel layer. PF significantly inhibited cell
invasion in both cell lines (Figure 4A). Migration was also evaluated
with Transwell assays. There was a significant decrease in cell
migration in both cell lines following increasing concentrations of PF
(Figure 4B). In both invasion and migration, the changes noted were
at concentrations of PF that were well below the calculated LD50 for
the cell lines, indicating that these changes were not simply secondary
to cell death.
Figure 2. FAK knockdown with siRNA. (A) RD and SJCRH30 cells were treated with negative control siRNA (siNeg) or multiple
independent siRNAs specific for FAK (siFAK2, siFAK3, siFAK4, 20 nM) for 48 hours. Immunoblotting for FAK showed decreased FAK
expression in both cell lines with siFAK treatment. (B) RD and SJCRH30 cells were treated with siFAK2, 3, or 4 (20 nM) for 48 hours;
cellular viability was measured using alamarBlue assay and reported as fold change in viability. In both cell lines, viability decreased
significantly following treatment with siFAK knockdown. (C) RD and SJCRH30 cells were treated with siFAK2, 3, or 4 (20 nM) for 48 hours,
and cellular proliferation was measured using CellTiter 96. There was a decrease in proliferation in both cell lines that was significant from
the cells treated with siNeg. Data were from three independent experiments and reported as mean fold change ± SEM.
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Cell Survival, and Motility
PF was not formulated for use in vivo[20], and we wished to
advance these studies to an animal model. Therefore, we chose to
investigate 1,2,4,5-benzenetetraamine tetrahydrochloride (Y15), one
of only a few small molecule FAK inhibitors that can be used in
animals [15,16]. Y15 has been previously described and was designed
to inhibit Y397 phosphorylation of FAK [14] but also inhibits total
FAK expression [15,16]. Using immunoblotting, we showed that Y15
decreased FAK expression in both the RD and SJCRH30 cell lines
(Figure 5A). Next, we examined how Y15 treatment affected cell
viability using alamarBlue assays. Both RD and SJCRH30 cell lines
showed significantly decreased cell viability following treatment with
Y15 (Figure 5B). The calculated LD50 for Y15 was 23 μM in the RD
and 7 μM in the SJCRH30 cell line. Additionally, the cell death
caused by Y15 in both cell lines was via apoptosis, as demonstrated by
decreased total PARP by immunoblotting (Figure 5C). Caspase 3
cleavage was also measured with a detection kit, and in the RD cell
line following Y15 treatment, there was cleavage of caspase 3 further
demonstrating apoptosis (Figure 5D). Cell proliferation was evaluated
with CellTiter 96 assays. There was a significant decrease in
proliferation in both cell lines following treatment with Y15 for 48
hours (Supplemental Data Figure S1B).
Phenotypic changes in the RD and SJCRH30 tumor cell lines
following Y15 treatment were further evaluated with cell invasion and
migration. RD and SJCRH30 cells were treated with increasingconcentrations of Y15. Invasion was measured after 48 hours, and
there was a significant decrease in invasion in both cell lines with Y15
(Figure 6A). In addition, after 24 hours of Y15, the cell lines showed a
marked decrease in migration by Transwell assay (Figure 6B). As seen
with PF, the phenotypic changes following Y15 occurred at concentra-
tions well below the LD50 concentration of Y15 for both cell lines,
indicating that these findings were not solely due to cell death.
1,2,4,5-Benzenetetraamine Tetrahydrochloride (Y15)
Treatment In Vivo
To test the in vivo effects of FAK inhibition, a nude mouse model of
RMSwas used. RDhumanERMS cells (2.5 × 106) were injected into the
right flank of 6-week-old female athymic nude mice (n = 25). Tumors
were measured every 2 days, and tumor volumes were calculated with the
standard formula of [(width)2 × length]/2, where width is the shorter
length. When tumors reached 200 mm3, animals were randomized to
receive intraperitoneal injections with either control (saline, n = 10) or
Y15 (n = 15) for 2 weeks. Data were reported as change in tumor volume
from the time treatment began. Animals treated with Y15 had
significantly less tumor growth than control-treated animals (P = .05)
(Figure 7, A and B). The time for tumor tripling was increased in the
Y15-treated tumors compared with vehicle-treated tumors but did not
reach statistical significance (5.1 ± 1.8 days vs 6.3 ± 1.3 days, NS, vehicle
vs Y15). To demonstrate target knockdown, tumor lysates were examined
using immunoblotting for FAK expression. Representative immunoblots
are shown in Figure 7C. Tumors from Y15-treated animals had less FAK
Figure 3. PF-573,228 (PF) inhibition of pY397FAK in human RMS cell lines. (A) RD and SJCRH30 cell lines were treated for 48 hours with
increasing concentrations of PF. Cell lysates were harvested and evaluated with immunoblotting for total FAK and pY397FAK. Increasing
concentrations of PF led to decreased pY397FAK in both cell lines. (B) AlamarBlue assays were used to assess cell viability. Both RD and
SJCRH30 cell lines showed significantly decreased cell viability following treatment with PF for 48 hours. (C) Immunoblotting for cleaved
PARP was utilized to detect apoptosis. RD and SJCRH30 cell lines were treated with PF for 48 hours, and cell lysates were collected.
Immunoblotting showed increased cleaved PARP following PF treatment in both cell lines, indicating apoptosis. (D) RD and SJCRH30 cell
lines were treated with PF at increasing concentrations for 48 hours, and caspase 3 activation was measured with a detection kit to
document apoptosis. Significant increases in activated caspase 3 were detected in both cell lines. Data were from three independent
experiments and reported as mean fold change ± SEM.
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to compare immunoblots from xenograft specimens, confirming
decreased FAK expression after Y15 treatment (Figure 7C). Cell
proliferation was measured in the tumor xenografts with immunohisto-
chemistry staining for Ki67. The percentage of Ki67-positive cells was
significantly decreased in the tumors treated with Y15 (49 ± 6% vs 64 ±
6%, Y15 vs control,P = .03). Representative photomicrographs (20×) are
presented in Supplemental Data Figure S2, with negative controls
reacting appropriately (Supplemental Data Figure S2, small insert,
left panel).
SJCRH30 human ARMS cells (2.0 × 106) were injected into the
right flank of 6-week-old female athymic nude mice (n = 25). Tumors
were measured every 2 days, and tumor volumes were calculated as
above. When tumors reached 200 mm3, animals were randomized to
receive intraperitoneal injections with either control (saline, n = 10)
or Y15 (n = 15) for 2 weeks. Animals treated with Y15 had
significantly less tumor growth than control-treated animals (Figure 7,
D and E). The tripling time of the vehicle-treated tumors wassignificantly shorter than that of the Y15-treated animals (4.4 ± 1.0
days vs 9.9 ± 1.8 days, P ≤ .02, vehicle vs Y15). Knockdown of the
target protein, FAK, was demonstrated by immunoblotting, showing
that tumors treated with Y15 had less FAK protein than controls
(Figure 7F). Densitometry was used to compare immunoblots from
xenograft specimens, confirming decreased FAK expression after Y15
treatment (Figure 7F). The effect of Y15 upon tumor cell
proliferation was evaluated with immunohistochemistry for Ki67.
Tumors treated with Y15 had significantly less Ki67-positive
cells than control-treated tumors (12 ± 6% vs 25 ± 4%, Y15 vs
control, P = .05). Representative photomicrographs are displayed in
Supplemental Data Figure S3. Negative control staining reacted
appropriately (Supplemental Data Figure S3, bottom insert, left panel).
Discussion
RMS continues to pose a therapeutic challenge, highlighting the need
for novel therapies. In this study, we explored the role of FAK in the
tumorigenesis of two histologic and genetic subtypes of RMS:
Figure 4. PF-573,228 (PF) treatment reduced invasion andmigration of RMS cell lines. (A) RD and SJCRH30 cell lines were treated with PF
at increasing concentrations and allowed to invade into a Matrigel-coated micropore insert for 48 hours. Invasion was reported as fold
change in the number of cells invading. PF treatment resulted in a significant decrease in invasion in both cell lines at low concentrations
of PF. (B) RD and SJCRH30 cell lines were treated with increasing concentrations of PF and allowed to migrate through amicropore insert
for 24 hours. Migration was reported as fold change in the number of cells migrating through the membrane. Migration was significantly
diminished following treatment with PF at a concentration of 1 μM. Data were from three independent experiments and reported as mean
fold change ± SEM.
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RD—embryonal (ERMS), fusion negative. The rationale for the
study of FAK in RMS was based upon the previous observations that
kinases upstream or downstream from FAK have been identified as
having a significant impact upon the tumorigenicity of RMS. For
instance, inhibition of the upstream kinas, Src has been noted to
decrease RMS cell growth both in vitro and in vivo[22]. Inhibition of
Akt, a kinase downstream to FAK, has also been shown to inhibit
RMS growth [23,24]. In addition, FAK was reported to be present in
HT-1080 cells, a fibrosarcoma cell line [17]. These previous studies
prompted us to hypothesize that FAK would be important in RMS
and supported the need to describe its role in these tumors.
In the current investigations, we reported that FAK was expressed
in human RMS tumor specimens, both ARMS and ERMS subtypes.
To our knowledge, these findings are novel and have not been
previously reported in the literature. Finding total and phosphory-
lated FAK in both subtypes has important clinical implications in that
it implies that potential therapeutic interventions utilizing FAK
inhibition would not be limited to a single subtype of RMS. Although
both pY397FAK and FAK were detected in both ARMS and ERMS,
there were factors precluding its use as a prognostic indicator. Because
FAK and pY397FAK have been shown to be expressed in normal
skeletal muscle [25,26], there was no opportunity to utilize normal
tissue to assist in quantitating staining. Additionally, there was not
enough of a difference in staining among the specimens, with almost
all of them showing mild to moderate staining, and perhaps the
limited number of specimens inhibited detection of small differences.
Evaluations of Ewing sarcoma specimens have shown similar results
[19,27] in that staining for FAK did not predict patient outcomes.
Ren et al. did find that, in osteosarcoma, the presence of FAK protein
and phosphorylation in human specimens correlated with both worse
overall survival and worse metastasis-free survival [28]. Clearly, FAK
may play an important role in multiple types of sarcomas, and perhaps
FAK overexpression is a universal phenomenon not only for sarcomas
but also for multiple solid tumors because it has been shown to be
overexpressed in breast, colon, thyroid, head and neck, prostate, and
ovarian cancers [29–33].It was noted that the baseline FAK expression in the SJCRH30 cell
line was less than that in the RD cell line, although the FAK
phosphorylation was greater in the SJCRH30 cells. These findings
may explain the observation that the SJCRH30 cell line was more
sensitive to PF-induced inhibition of FAK phosphorylation, but these
cells were also, in many regards, more sensitive to overall inhibition of
FAK protein as seen with Y15 inhibitor. Obviously, it would follow
that if the total protein were decreased, the amount of phosphorylated
protein would also be decreased, leading to this finding. These
findings could also be explained by the idea of oncogene addiction.
Investigators have postulated that certain tumor cell lines are
physiologically more dependent upon specific survival factors, and
inhibition of these specific cellular factors will have a more profound
effect upon those cells than others even of the same tumor type [34],
regardless of their degree of expression. Another explanation is that
there may be significant differences between cell lines that have the
signature PAX-FOXO1 fusion (SJCRH30) [18] and those that do not
(RD), which would actually be an important finding because those
tumors are the most aggressive and difficult to treat. Investigations
into this hypothesis will certainly be the subject of future studies.
We found varying extents of change in PARP and caspase 3
depending upon the cell line and the agent utilized for FAK
inhibition. These findings are likely due to differences in cell lines.
Storch and colleagues had similar results when they examined PARP
and caspase 3 in glioblastoma cell lines treated with FAK inhibition
[35]. Four different ovarian cancer cell lines also had varying levels of
PARP cleavage and caspase 3 activation with FAK inhibition [36].
The small molecule FAK inhibitor PF-573,228 was utilized in
these studies to corroborate the siRNA findings that FAK was an
important survival signal and a potential target in RMS tumors.
PF-573,228 has been shown to block the FAK catalytic activity by
binding to the ATP pocket of FAK [20]; decreasing cell survival,
migration, and invasion [12,19]; as well as diminishing metastatic
potential [37] and enhancing chemotherapy-induced cytotoxicity
[38]. In an effort to minimize off-target effects associated with small
molecule inhibitors, PF-573,228 was chosen over another FAK
inhibitor, PF-562,271, because PF-562,271 affects PyK2 in addition
Figure 5. 1,2,4,5-Benzenetetraamine tetrahydrochloride (Y15) inhibition of FAK in human RMS cell lines. (A) RD and SJCRH30 cells were
treated with increasing concentrations of Y15 for 24 hours, and lysates were collected. Immunoblotting showed decreased FAK
expression in both cell lines. FAK phosphorylation followed total FAK expression. (B) AlamarBlue assay was used to measure cell viability.
RD and SJCRH30 cells were treated with Y15 at increasing concentrations for 24 hours. Cell viability was significantly decreased with
treatment of 5-μM concentration in both cell lines. (C) Immunoblotting was utilized to detect apoptosis. There was a decrease in total
PARP detected in cell lysates from the RD and SJCRH30 cell lines after treatment with Y15, indicating apoptosis. (D) Apoptosis was also
detected using a caspase 3 activation kit. Y15 resulted in a significant increase in caspase 3 activation in the RD cell line. Data were from
three independent experiments and reported as mean fold change ± SEM.
Figure 6. 1,2,4,5-Benzenetetraamine tetrahydrochloride (Y15) decreased cell invasion and migration. (A) RD and SJCRH30 cells were
treated with increasing concentrations of Y15 and allowed to invade through aMatrigel-coatedmicropore insert. Invasion was reported as
fold change in number of cells invading. Invasion was significantly decreased in both cell lines with increasing concentrations of Y15. (B).
RD and SJCRH30 cells were treated with increasing concentrations of Y15 for 24 hours and allowed to migrate through a micropore
insert. Migration was reported as fold change in number of cells migrating through the membrane. Migration was significantly decreased
in both RMS cell lines with Y15 treatment, beginning at 1.0-μM concentration. Data were from three independent experiments and
reported as mean fold change ± SEM.
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Figure 7. Treatment with 1,2,4,5-benzenetetraamine tetrahydrochloride (Y15) inhibited growth of human RMS xenografts. (A) RD
embryonal RMS cells (2.5 × 106 cells/100 μl of sterile PBS) were injected into the subcutaneous space of the right flank of female nude
mice (n = 25). When tumors reached 200 mm3, the animals were randomized to daily intraperitoneal injection of control vehicle (n = 10)
or Y15 (n= 15). Tumor volumes were measured and reported as fold change in tumor volume. Animals treated with Y15 had significantly
less change in tumor volume compared with control-treated animals. (B) Representative photographs demonstrating differences in
tumors between control and Y15-treated animals. (C) To confirm target knockdown in the RD specimens, immunoblotting for FAK was
performed on xenograft tumor lysates. Tumors were homogenized, proteins wer separated on SDS-PAGE gels, and immunoblotting for
FAK was performed, with representative immunoblots shown. There was a decrease in FAK in the tumors from the animals that received
Y15 treatment. These findings were further demonstrated by densitometry, with a decreased FAK:β-actin ratio. (D) SJCRH30 RMS cells
(2.0 × 106 cells/100 μl of sterile PBS) were injected into the subcutaneous space of the right flank of female nude mice (n = 25). When
tumors reached 200 mm3, animals were randomized to daily intraperitoneal injection of control vehicle (n = 10) or Y15 (n = 15). Tumor
volumes were measured and reported as fold change in tumor volume. Animals treated with Y15 had significantly smaller change in
tumor volume compared with controls. (E) Representative photographs demonstrating differences in tumors between animals treated
with Y15 and controls. (F) To confirm target knockdown in the SJCRH30 specimens, immunoblotting for FAK was performed on xenograft
tumor lysates. Representative immunoblots are shown. There was a decrease in FAK in the tumors from the animals that received Y15
treatment. These findings were further demonstrated by densitometry, showing a decreased FAK:β-actin ratio.
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was not suitable for use in vivo; therefore, Y15 was utilized. Y15 has
been previously described for in vivo use in a number of tumor
models [14,16,19,40].
The metastatic potential of RMS cell lines appeared to be decreased
as noted by decreased migration and invasion of the tumor cells
following PF or Y15 treatment. The ability to metastases in a
preclinical mouse model of RMS is currently difficult [41].
Subcutaneous injections of these cell lines do not routinely result in
metastases that compare to the human condition. Tail vein injections
of RMS result in intraperitoneal implants of tumor, but again, these
conditions are far removed from those noted clinically in humans.
Therefore, we were not able to explore this aspect of FAK inhibition
in the current studies.The small molecules PF-573,228 and Y15 have been reported to
inhibit FAK phosphorylation at the Y397 autophosphorylation site
[14,20]. In our study, we did see inhibition of pY397FAK in both cell
lines with the PF-573-228, but the Y15 primarily affected total FAK
expression and thereby subsequent FAK phosphorylation. Similar
findings have been reported with other cell lines. Y15 treatment of the
human pancreatic cell line Panc 1 decreased total FAK [15]; Y15 also
resulted in decreased total FAK in studies with BT474 breast cancer
cells [14] and U87 glioma cells [42].
In summary, we showed that multiple approaches to FAK
abrogation including siRNA and small molecules diminished the
malignant phenotype of RMS cell lines. There were a significant
decrease in cell survival, an increase in apoptosis, and a decrease in
both migration and invasion. An important observation was that the
272 FAK supports rhabdomyosarcoma tumorigenicity Waters et al. Translational Oncology Vol. 9, No. 4, 2016changes in migration and invasion following small molecule FAK
inhibition occurred at concentrations below the LD50 of the
inhibitors because cells that are not viable will not invade or migrate.
Another novel aspect of the current studies was the demonstration
that FAK inhibition in a nude mouse model of RMS resulted in
significantly smaller and less proliferative tumors when compared
with controls. We believe that the data presented provide justification
for further investigations of FAK inhibition as a potential therapeutic
strategy for difficult-to-treat RMS.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.tranon.2016.06.001.
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